Quantum convoy covers 1,000 miles for cancer

Pharmaceutical specials manufacturer raises £5,000 for charity

Ten amateur cyclists from pharmaceutical manufacturer Quantum Pharmaceutical have completed a 1,000-mile charity bike ride to raise £5,000 for Marie Curie Cancer Care.

The team signed up for the challenge after their colleague Tony Gallagher died of cancer in 2008.

Gallagher’s son, Scott, led the cycle convoy, which rode off from Land’s End in Cornwall and cycled up to 90 miles a day to cross the finishing line at John O’Groats in Caithness, Scotland a fortnight later.

‘It was a testing couple of weeks,’ said Quantum Pharmaceutical’s managing director Andy Scaife.

‘We remember Tony so fondly, and cycling a thousand miles will be nothing compared with the challenge he faced in fighting cancer. We just hope the money we raise will help other cancer sufferers as they battle with the disease.’

Quantum Pharmaceutical, based in Burnopfield, Co Durham, UK, is a pharmaceutical specials manufacturer licensed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to supply pharmacies, chemists, dispensing doctors and hospitals with bespoke medicines.

You may also like

Regulatory

Penn Pharma recalls batches of seizure drug

Following incorrect placement of screw caps on some units of Midazolam buccal liquid, which could affect drug concentration
Containment

Quantum Pharmaceutical opens aseptic manufacturing facility

Incorporates aseptic compounding and manufacturing services, including gassing isolators
Manufacturing

Quantum Pharmaceutical moves into new HQ

Opens up potential for further expansion of the UK specials manufacturer
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Drug Delivery

Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies

The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Subscribe now